Skip to main content
Smart Investors Daily
Sandoz Group AG logo

OTC · SDZNY

Sandoz Group AG

Healthcare · Drug Manufacturers - Specialty & Generic

$101.21

Up+$0.55 (+0.55%)

Updated Nov 5, 2026, 12:15 AM

SID Score

5.0/10

Composite research score

Smart Money

46/100

Neutral

Market cap
32.05B
P/E ratio
140.61
Dividend yield
0.72%
52-week range
— – —
Volume
1.37K
Avg. volume
23.64K

Price performance · SDZNY

SDZNY price history

1M range · 0 trading sessions · Daily adjusted prices

SDZNY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SDZNY news

The latest Smart Investors Daily articles mentioning SDZNY.

SDZNY research

Overview

Company profile and research snapshot.

Company profile

SANDOZ GROUP AG S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$66.64
Implied upside
—
Analysts
18
SDZNY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 23, 2026JEFFERIESBuy—
Sep 21, 2026BERENBERGHold—
Sep 17, 2026BAADER EUROPE / ALPHAVALUEBuy—
Aug 31, 2026BNP PARIBASNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

A new Sandoz analysis reveals the next wave of affordable medicines is coming; will Canada be ready?

The next decade will see more than 300 brand-name medicines lose exclusivity or have already become open to competition but have not yet seen market entry, opening the door to a new generation of affordable generic and biosimilar treatments for Canadians. To better understand the scale of this opportunity, Sandoz Canada conducted an in-depth analysis. Aviseo Conseil independently assessed the economic and methodological coherence of the forecasting framework and the overall plausibility of its o

Yahoo · Oct 28, 2026

Sandoz stock falls on sales outlook cut, Q3 miss

Investing.com -- Sandoz Group AG cut its full-year sales forecast while lifting core earnings margin outlook after the company reported worse-than-expected sales for the third quarter. The company’s shares fell nearly 5%.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.